US 12,215,166 B2
Bispecific antigen binding constructs targeting HER2
Nina E. Weisser, Delta (CA); Gordon Yiu Kon Ng, Vancouver (CA); Grant Raymond Wickman, Vancouver (CA); Surjit Bhimarao Dixit, Richmond (CA); Eric Escobar-Cabrera, Vancouver (CA); and Mario Sanches, Vancouver (CA)
Assigned to Zymeworks BC Inc., Vancouver (CA)
Filed by ZYMEWORKS BC INC., Vancouver (CA)
Filed on Apr. 25, 2022, as Appl. No. 17/728,491.
Application 15/863,464 is a division of application No. 15/036,176, granted, now 10,947,319, issued on Mar. 16, 2021, previously published as PCT/CA2014/051140, filed on Nov. 27, 2014.
Application 17/728,491 is a continuation of application No. 16/011,048, filed on Jun. 18, 2018, granted, now 11,325,981.
Application 16/011,048 is a continuation of application No. 15/863,464, filed on Jan. 5, 2018, granted, now 10,000,576, issued on Jun. 19, 2018.
Claims priority of provisional application 62/009,125, filed on Jun. 6, 2014.
Claims priority of provisional application 62/000,908, filed on May 20, 2014.
Claims priority of provisional application 61/910,026, filed on Nov. 27, 2013.
Prior Publication US 2023/0118302 A1, Apr. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/32 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/32 (2013.01) [A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/68033 (2023.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); A61K 47/6869 (2017.08); C07K 16/3015 (2013.01); C07K 16/3069 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 23 Claims
 
1. An isolated antigen binding construct comprising:
(a) a first antigen-binding polypeptide construct which specifically binds a HER2 (human epidermal growth factor receptor 2) ECD2 (extracellular domain 2) antigen on a HER2-expressing cell, wherein the first antigen binding polypeptide construct comprises a first heavy chain variable region (VH1) and a first light chain variable region (VL1), wherein the VH1 comprises the sequence shown in SEQ ID NO:99 and the VL1 comprises the sequence shown in SEQ ID NO:71; and
(b) a second antigen binding polypeptide construct which specifically binds a HER2 ECD4 (extracellular domain 4) antigen on a HER2-expressing cell, wherein the second antigen binding polypeptide construct comprises a second heavy chain variable domain (VH2) and a second light chain variable domain (VL2), wherein the VH2 comprises the sequence shown in SEQ ID NO: 305 and the VL2 comprises the sequence shown in SEQ ID NO:297, and wherein the second antigen binding polypeptide construct is operably linked to the first antigen binding polypeptide construct.